The survival benefit achieved with adjuvant therapy was most pronounced
for women with estrogen receptor (ER)-positive
breast cancer. Among these women, at 5 years, the overall and disease-free survival rates in the adjuvant therapy group were 88 percent and 83 percent, respectively, while the corresponding rates in the observation group were 74 percent and 61 percent. Once again, the differences persisted at 10 years.